Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
作者信息
Fung Monica, Schwartz Brian S, Doernberg Sarah B, Langelier Charles, Lo Mimi, Graff Larissa, Tan Marisela, Logan Aaron C, Chin-Hong Peter, Babik Jennifer M
机构信息
Division of Infectious Diseases, University of California San Francisco.
Department of Pharmacy, University of California San Francisco.
出版信息
Clin Infect Dis. 2018 Sep 14;67(7):1142-1143. doi: 10.1093/cid/ciy260.
Abstract
摘要
相似文献
1
Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
Clin Infect Dis. 2018 Sep 14;67(7):1142-1143. doi: 10.1093/cid/ciy260.
2
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613. doi: 10.1093/cid/ciy406.
3
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Mycoses. 2018 Jul;61(7):485-497. doi: 10.1111/myc.12777. Epub 2018 Apr 26.
4
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
Leuk Lymphoma. 2019 Feb;60(2):527-530. doi: 10.1080/10428194.2018.1485913. Epub 2018 Jul 24.
5
[Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
Rev Iberoam Micol. 2018 Oct-Dec;35(4):192-197. doi: 10.1016/j.riam.2018.07.003. Epub 2018 Nov 16.
6
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
Transpl Infect Dis. 2021 Apr;23(2):e13469. doi: 10.1111/tid.13469. Epub 2020 Nov 4.
7
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01634-18. Print 2019 Jan.
8
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
Med Mycol. 2020 Jun 1;58(4):417-424. doi: 10.1093/mmy/myz103.
9
Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Ann Clin Microbiol Antimicrob. 2019 Mar 20;18(1):13. doi: 10.1186/s12941-019-0311-3.
10
[Invasive aspergillosis in solid organ transplantation].
Rev Iberoam Micol. 2018 Oct-Dec;35(4):206-209. doi: 10.1016/j.riam.2018.05.002. Epub 2018 Nov 20.
引用本文的文献
1
Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis.
Open Forum Infect Dis. 2025 Mar 14;12(4):ofaf163. doi: 10.1093/ofid/ofaf163. eCollection 2025 Apr.
2
Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.
J Pediatr Hematol Oncol. 2024 Mar 1;46(2):e143-e146. doi: 10.1097/MPH.0000000000002812. Epub 2024 Jan 17.
3
Subcutaneous zygomycosis in an immunocompetent patient caused by .
BMJ Case Rep. 2023 Jan 5;16(1):e253515. doi: 10.1136/bcr-2022-253515.
4
Mucormycosis co-infection in COVID-19 patients: An update.
Open Life Sci. 2022 Aug 10;17(1):917-937. doi: 10.1515/biol-2022-0085. eCollection 2022.
5
Isavuconazole for COVID-19-Associated Invasive Mold Infections.
J Fungi (Basel). 2022 Jun 28;8(7):674. doi: 10.3390/jof8070674.
6
Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.
Front Microbiol. 2022 Jan 4;12:794176. doi: 10.3389/fmicb.2021.794176. eCollection 2021.
7
Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole.
Antibiotics (Basel). 2021 Apr 23;10(5):487. doi: 10.3390/antibiotics10050487.
8
In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.
J Fungi (Basel). 2021 Apr 2;7(4):271. doi: 10.3390/jof7040271.
9
Isavuconazole-Animal Data and Clinical Data.
J Fungi (Basel). 2020 Oct 6;6(4):209. doi: 10.3390/jof6040209.
10
[Non-aspergillus molds infection after allogeneic stem cell transplantation: clinical analysis of 24 cases and outcomes].
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):624-629. doi: 10.3760/cma.j.issn.0253-2727.2020.08.002.
本文引用的文献
1
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613. doi: 10.1093/cid/ciy406.
2
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7.
3
Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Clin Microbiol Infect. 2017 Nov;23(11):882-887. doi: 10.1016/j.cmi.2017.03.023. Epub 2017 Apr 1.
4
Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.
Clin Infect Dis. 2017 Jun 1;64(11):1619-1621. doi: 10.1093/cid/cix130.
5
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.
6
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.
7
Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Antimicrob Agents Chemother. 2015 Apr;59(4):2078-85. doi: 10.1128/AAC.04569-14. Epub 2015 Jan 26.
8
Antifungal prophylaxis in lung transplantation--a world-wide survey.
Am J Transplant. 2011 Feb;11(2):361-6. doi: 10.1111/j.1600-6143.2010.03375.x. Epub 2011 Jan 10.
9
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
Clin Infect Dis. 2008 Sep 1;47(5):674-83. doi: 10.1086/590566.
Zotero 插件